DELTA-Q-TECHNOLOGIES
2.5.2023 15:01:29 CEST | Business Wire | Press release
Delta-Q Technologies (Delta-Q), a leader in battery charging solutions for electric vehicles and industrial equipment, has announced that its innovative mid-power charger, the XV3300, is now in full-scale production. With its unique 3-in-1 design, this highly efficient charging system integrates a 3.3 kW battery charger, a 500 W DC-DC converter to power the vehicles’ auxiliary loads, and an EV charging station interface. These key features, encased in a ruggedized IP67 design, provide OEMs with an attractive package for simplifying electrification of their off-road applications.
“No other 3.3 kW charger on the market also includes a DC/DC converter for auxiliary DC loads and an EVSE charging interface in such a compact size,” said Mourad Chergui, Senior Product Manager with Delta-Q. “As we start full-scale production, we can begin to fulfill the substantial demand we received since we first announced the initial development.”
The 3.3 kW charging solution is available in 58.8, 65, and 120-volt DC models and is scalable, allowing OEMs to stack up to three chargers for power levels up to 10 kW. The XV3300 uses complex algorithms to deliver a precise charge to batteries of various chemistries and voltages, maximizing battery life and optimizing charge time.
Key features and benefits of the XV3300 charger include:
- High Reliability: The XV3300 battery charger is compact, rugged, and IP67-rated. It is tested for automotive-grade shock and vibration. Its fully sealed aluminum die-cast enclosure protects the charger from dust, liquids, and the effects of immersion in up to one meter of water.
- Enhanced Protection: The XV3300 is a low-voltage charger that optimally charges all battery chemistries and nominal voltages between 48 V to 120 V. It is also protected against short circuits, over-voltage, and over-temperature to ensure safe operation.
- Flexible Power Options: The XV3300 is scalable and can be paralleled to provide between 3.3 kW to 10 kW of power for faster-charging options. The charger is also available as an on-board and off-board charger, providing OEMs with additional flexibility.
- Integrated DC-DC converter: It provides auxiliary power to operate vehicle accessories such as air-conditioners, controllers, lights, turn signals, navigation, and communication devices. It also eliminates the need for an external DC-DC converter, saving OEMs and equipment operators space and cost.
- EV Charging Station Interface: The XV3300 complies with SAE J1772 (levels 1 and 2) and IEC 61851 (modes 2 and 3) to charge from standard EVSE AC charging stations across North America and Europe. This feature provides end-users more charging options and greater vehicle flexibility.
To register for updates on the XV3300 battery charger or for specific details, including product specifications, visit https://connect.delta-q.com/xv3300.
About Delta-Q Technologies
Delta-Q Technologies is charging the future and driving the world’s transition to electric energy. We collaboratively design, test, and manufacture robust battery chargers that improve the performance of our customers’ electric drive vehicles and industrial machines. As the supplier of choice for Tier 1 OEMs, our customer support and engineering expertise guide our customers through the electrification process for a sustainable world.
Delta-Q is part of the ZAPI GROUP of companies and headquartered in Vancouver, Canada. The team and distribution span five continents to service industries such as electric golf cars, lift trucks, aerial work platforms, e-mobility, floor care machines, utility/recreational vehicles, and new markets, like construction and outdoor power equipment. Please visit www.delta-q.com or follow company updates on LinkedIn for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom